Caris Life Sciences, Inc. Common Stock (CAI)vsNovartis AG ADR (NVS)
CAI
Caris Life Sciences, Inc. Common Stock
$15.59
0.00%
HEALTHCARE · Cap: $4.66B
NVS
Novartis AG ADR
$159.85
-0.64%
HEALTHCARE · Cap: $290.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6149% more annual revenue ($56.69B vs $907.29M). NVS leads profitability with a 22.5% profit margin vs 3.8%. NVS earns a higher WallStSmart Score of 51/100 (C-).
CAI
Hold44
out of 100
Grade: D
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CAI.
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$159.85
$67.31 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 78.8% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
ROE of 5.7% — below average capital efficiency
3.8% margin — thin
Operating margin of 2.4%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CAI
The strongest argument for CAI centers on Revenue Growth. Revenue growth of 78.8% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bear Case : CAI
The primary concerns for CAI are EPS Growth, Return on Equity, Profit Margin. Thin 3.8% margins leave little buffer for downturns.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
CAI profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
CAI is growing revenue faster at 78.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 44/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Caris Life Sciences, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CAI International, Inc. is a transportation finance company in the United States, Switzerland, France, Korea, Singapore, Rest of Asia, Rest of Europe, and internationally. The company is headquartered in San Francisco, California.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?